Active, not recruiting |
: Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Malignant Ovarian Mixed Epithelial Tumor
- Ovarian Brenner Tumor<
: 2009-08-01
: - Biological: Bevacizumab Given
|
Completed |
: Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
: - Fallopian Tube Carcinoma
- Malignant Ovarian Mixed Epithelial Tumor
-
- Drug: Carboplatin Given IV
|
Active, not recruiting |
: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
: - Cognitive Side Effects of Cancer Therapy
- Malignant Ovarian Epithelial Tumor
-
- Procedure: Cognitive Assessment
|
Completed |
: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Carcinoma
- Malignant Ovarian Mixed Epithelial Tumor
-
- Biological: Urokinase-Derived Peptide A6
|
Recruiting |
: MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer
: - Malignant Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcino
: 2014-02-19
: - Other: Laboratory Biomarker Analysis
|
Withdrawn |
: Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
: - Fatigue
- Malignant Ovarian Mixed Epithelial Tumor
- Neuropath
: 2011-12-14
: - Dietary Supplement: Acetyl-L-Carnitine Hydrochloride
|
Active, not recruiting |
: Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
: - Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
: 2010-07-21
: - Biological: Bevacizumab Given
|
Active, not recruiting |
: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
: 2010-02-23
: - Drug: Bortezomib Given IP
|
Active, not recruiting |
: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
: 2009-04-24
: - Drug: Elesclomol Sodium Given
|
Active, not recruiting |
: Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
: 2005-04-18
: - Other: Clinical Observation Un
|